ORTHOCELL LIMITED — Capital/Financing Update 2018

Jan 11, 2018

==> picture [594 x 111] intentionally omitted <==

Successful completion of Orthocell Share Purchase Plan

• Strong shareholder response to Orthocell’s SPP, which follows the recent placement

• 4.3m new shares raising approximately A$1.5m from the SPP, were allotted today, 12 January 2018

• Placement and SPP raised approximately A$3m to accelerate CelGro® commercialisation and progress US regulatory approvals and key studies, advance the development of Ortho-ATI® and R&D pipeline

Perth, Australia; 12 January 2018: Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) is pleased to report the successful completion of the Company’s Share Purchase Plan (“SPP”), with a pleasing shareholder response following the recent completion of the placement (“Placement”) in December 2017.

Orthocell Managing Director Paul Anderson said: “We would like to thank our shareholders for their continued support, particularly during the busy holiday period. We are very pleased with the successful completion of both the Placement and the SPP, and we look forward to progressing our commercialisation and clinical milestones into the new year.”

The SPP was announced to the market on 13 December 2017 and successfully closed at 5pm AEDT on 5 January 2018. Applications for approximately 4.3m new fully paid ordinary shares were received, raising approximately A$1.5m.

Successful eligible SPP applicants have been issued new shares at A$0.34 per share, the same price as the placement. No scaleback of applications occurred and participating shareholders were issued the full amount of the new shares for which they applied, up to a maximum of A$15,000. The new shares were allotted today, 12 January 2018.

The total amount raised under the Placement and the SPP is approximately A$3.0m and the combined proceeds and cash reserves will be used to accelerate CelGro® commercialisation and progress US regulatory approvals and key studies, advance the development of Ortho-ATI® and other R&D pipeline products.

Ph: +61 8 9360 2888 Fax: +61 8 9360 2899 www.orthocell.com.au

==> picture [594 x 111] intentionally omitted <==

For more information, please contact:

General enquiries

Investor enquiries

Media enquiries

Paul Anderson Joel Seah Ben Walsh Orthocell Limited, Managing Vesparum Capital WE Buchan Director P: +61 3 8582 4800 P: +61 411 520 012 P: +61 8 9360 2888 E: orthocell@vesparum.com E: bwalsh@buchanwe.com.au E: paulanderson@orthocell.com.au

About Orthocell Limited

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of soft tissue injuries. Orthocell’s portfolio of products include TGA-licensed cell therapies Autologous Tenocyte Implantation (Ortho-ATI®) and Autologous Chondrocyte Implantation (Ortho-ACI®), which aim to regenerate damaged tendon and cartilage tissue. The Company’s other major product is CelGro®, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications. Orthocell recently received European regulatory approval (CE Mark) for CelGro®. The collagen medical device can now be marketed and sold within the European Union for a range of dental bone and soft tissue regeneration procedures and is being readied for first approval in the US.

For more information on Orthocell, please visit www.orthocell.com.au or follow us on Twitter @Orthocellltd and Linkedin www.linkedin.com/company/orthocell-ltd

Ph: +61 8 9360 2888 Fax: +61 8 9360 2899 www.orthocell.com.au